Skip to main content
Premium Trial:

Request an Annual Quote

OvaGene Licenses Technologies for Potential MDx

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – OvaGene Oncology today announced it has completed licensing agreements with Norwegian researchers to validate new genomic technologies with the intention of developing them into clinical laboratory tests.

The Irvine, Calif.-based based firm has licensed a proprietary method from the University of Bergen Tech Office BTO for identifying high-risk endometrial cancer patients diagnosed with early-stage cancer. The technology can identify a molecular component in early-stage patients linked with high risk, OvaGene said in a statement.

It has also licensed a proprietary method from Medinnova for determining chemoradiation resistance in cervical cancer. Further studies are planned to validate the technology, which may allow patients to be tested for chemoradiation resistance before therapy is started.

Details about the agreements were not disclosed.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.